NEWTOWN, Pa., Dec. 5, 2014 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, will be hosting an investor and analyst event on Friday December 12, 2014 from 8:30 am to 12:00 pm ET in New York, NY. The program will focus on recent progress and advances with rigosertib for the treatment of patients with myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML). The event will feature presentations by leading experts in the fields of oncology and hematology and Onconova management.
Experts will include:
- Guillermo Garcia-Manero, M.D., Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center; Chief, Section of Myelodysplastic Syndromes, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center; Deputy Chair, Translational Research, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
- Thomas Prebet, M.D., Ph.D., Hematology Department, Institut Paoli Calmettes
- Lewis R. Silverman, M.D., Associate Professor Medicine, Hematology and Medical Oncology and Assistant Professor Oncological Sciences at the Icahn School of Medicine at Mount Sinai
The event is open to members of the professional investment community. For more information on attending please contact Michaela Parnell at email@example.com.
The event audio and slide presentation will be webcast live on the Company's website, www.onconova.com, on the Events & Presentations page under the Investors and Media tab.
About Onconova Therapeutics, Inc.
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its proprietary chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, two other candidates, briciclib and recilisib, are clinical stage, and several candidates are in pre-clinical stages. For more information, please visithttp://www.onconova.com.
CONTACT: Onconova Therapeutics Benjamin Hoffman, 267-759-3036 firstname.lastname@example.org or Media: MacDougall Biomedical Communications Chris Erdman, 781-235-3060 email@example.comSource:Onconova Therapeutics